{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:00:28Z","timestamp":1792814428654,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To characterize the post-marketing safety profile of etrasimod using the latest data from the FDA Adverse Event Reporting System (FAERS), and to provide a comparative analysis versus other sphingosine-1-phosphate (S1P) receptor modulators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>AE reports associated with etrasimod were retrieved from FAERS (Q1 2004 \u2013 Q2 2025). Disproportionality analyses were conducted using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS) methods. A comparative analysis against fingolimod and ozanimod was performed to contextualize findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 2,104 AE reports from 967 patients\u2014a larger cohort than previously described. The most frequent AEs were drug ineffectiveness, condition aggravated, headache, and dizziness. Signals were concentrated in gastrointestinal, general, and nervous system disorders. Strong signals included ulcerative proctitis, increased faecal calprotectin, and macular oedema. Critically, our comparative analysis suggested a potentially distinct safety profile for etrasimod, such as a more favorable signal for lymphocyte count decreased compared to other S1P modulators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This large-scale, updated analysis confirms the established safety profile of etrasimod while providing novel, comparative insights. Our findings, derived from the most recent and extensive FAERS dataset to date, underscore that etrasimod\u2019s real-world safety is characterized by class-related AEs and disease exacerbations. The lack of unexpected signals remains reassuring. The frequent reporting of lack of efficacy highlights the need for close monitoring, and the comparative data offer valuable context for clinicians selecting S1P receptor modulator therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1693090","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:33:22Z","timestamp":1762842802000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for etrasimod"],"prefix":"10.3389","volume":"16","author":[{"given":"Yingxiu","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S755","DOI":"10.1093\/ecco-jcc\/jjaa017","article-title":"JAK inhibitors safety in ulcerative colitis: practical implications","volume":"14","author":"Agrawal","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"B2","volume-title":"Pfizer receives positive CHMP opinion for ulcerative colitis treatment","author":"Are Made","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14712598.2020.1732919","article-title":"Modulation of sphingosine-1-phosphate in ulcerative colitis","volume":"20","author":"Argollo","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"B4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"e12836","DOI":"10.1111\/cmi.12836","article-title":"Sphingosine-1-phosphate receptors and innate immunity","volume":"20","author":"Bryan","year":"2018","journal-title":"Cell Microbiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1021\/ml500389m","article-title":"Discovery of APD334: design of a clinical stage functional antagonist of the Sphingosine-1-phosphate-1 receptor","volume":"5","author":"Buzard","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"B7","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1516991","DOI":"10.3389\/fphar.2025.1516991","article-title":"Sphingosine 1-phosphate receptor 1 modulators exert neuroprotective effects in central nervous system disorders","volume":"16","author":"Chen","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"jjae173","DOI":"10.1093\/ecco-jcc\/jjae173","article-title":"Low incidence of macular edema and other ocular events in the etrasimod development program","volume":"19","author":"Dubinsky","year":"2025","journal-title":"J. Crohns Colitis"},{"key":"B10","volume-title":"Highlights of prescribing information","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/2211-5463.13907","article-title":"Unique pharmacological properties of etrasimod among S1P receptor modulators","volume":"15","author":"Gaidarov","year":"2025","journal-title":"FEBS Open Bio."},{"key":"B12","doi-asserted-by":"publisher","first-page":"36558","DOI":"10.1038\/s41598-025-19679-z","article-title":"Safety evaluation of etrasimod for ulcerative colitis based on the FAERS database","volume":"15","author":"Guo","year":"2025","journal-title":"Sci. Rep."},{"key":"B13","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1212\/WNL.0b013e31820d5ec1","article-title":"Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation","volume":"76","author":"Hla","year":"2011","journal-title":"Neurology"},{"key":"B14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1212\/WNL.0b013e318248deea","article-title":"Fingolimod-associated macular edema: incidence, detection, and management","volume":"78","author":"Jain","year":"2012","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.2165\/00002018-200730050-00001","article-title":"Guidelines for submitting adverse event reports for publication","volume":"30","author":"Kelly","year":"2007","journal-title":"Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s11523-021-00841-2","article-title":"Niraparib: a review in first-line maintenance therapy in advanced ovarian cancer","volume":"16","author":"Lee","year":"2021","journal-title":"Target Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"17562848241293643","DOI":"10.1177\/17562848241293643","article-title":"Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: an analysis of the phase II OASIS and phase III ELEVATE UC 52 and ELEVATE UC 12 clinical trials","volume":"17","author":"Lees","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1290975","DOI":"10.3389\/fphar.2024.1290975","article-title":"A real-world disproportionality analysis of mesalazine data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Liu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1242\/dev.094805","article-title":"Sphingosine 1-phosphate signalling","volume":"141","author":"Mendelson","year":"2014","journal-title":"Development"},{"key":"B20","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.autrev.2017.03.007","article-title":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","volume":"16","author":"Peyrin-Biroulet","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B22","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.gastro.2019.10.035","article-title":"Efficacy and safety of etrasimod in a phase 2 randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine\u20101\u2010phosphate receptor\u20101 (S1P1) and receptor\u20105 (S1P5) agonist with autoimmune disease\u2010modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","article-title":"Reporting of thromboembolic events with JAK inhibitors: analysis of the FAERS database 2010-2019","volume":"44","author":"Setyawan","year":"2021","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40265-024-01997-7","article-title":"Etrasimod: first approval","volume":"84","author":"Shirley","year":"2024","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","first-page":"i701","DOI":"10.1093\/ecco-jcc\/jjac190.0705","article-title":"P575 effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials","volume":"17","author":"Siegmund","year":"2023","journal-title":"Precis. Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA technical review on the management of moderate to severe ulcerative colitis","volume":"158","author":"Singh","year":"2020","journal-title":"Gastroenterology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40263-015-0261-z","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis","volume":"29","author":"Subei","year":"2015","journal-title":"CNS Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1362484","DOI":"10.3389\/fphar.2024.1362484","article-title":"A pharmacovigilance study on antibody-drug conjugate (ADC)-related neurotoxicity based on the FDA adverse event reporting system (FAERS)","volume":"15","author":"Tang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e001516","DOI":"10.1136\/bmjgast-2024-001516","article-title":"Cardiovascular events observed among patients in the etrasimod clinical programme: an integrated safety analysis of patients with moderately to severely active ulcerative colitis","volume":"12","author":"Vermeire","year":"2025","journal-title":"BMJ Open Gastroenterol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase(\u00ae)","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1320458","DOI":"10.3389\/fphar.2023.1320458","article-title":"A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database","volume":"14","author":"Zou","year":"2023","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1693090\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:33:23Z","timestamp":1762842803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1693090\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":36,"alternative-id":["10.3389\/fphar.2025.1693090"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1693090","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"article-number":"1693090"}}